Related News
Home » Business » Manufacturing
Firms join hands in anticancer drug deal
Source: Agencies |
June 2, 2009, Tuesday
|
Print Edition
Print Edition
DRUG developers AstraZeneca Plc and Merck & Co said yesterday that they will jointly develop a combination treatment for cancer.
The firms said they will combine efforts with Merck's MK-2206 and AstraZeneca's AZD6244, both of which are still in very early development.
They said in a statement that pre-clinical studies - the laboratory phase of development - indicate the combination has potential as an anticancer drug.
The drug candidates are currently in separate early-stage studies involving people. Under the deal, the firms will jointly evaluate the combination in a Phase I clinical trial. They will share development costs.
Decisions on further development will be based on the early-stage study.
The early stages of drug development focus mainly on whether the compound is safe and can reach its intended target.
They normally only involve a small population of patients. Results from later stages of development, involving a higher number of patients, are used to see if a treatment actually works.
The firms said they will combine efforts with Merck's MK-2206 and AstraZeneca's AZD6244, both of which are still in very early development.
They said in a statement that pre-clinical studies - the laboratory phase of development - indicate the combination has potential as an anticancer drug.
The drug candidates are currently in separate early-stage studies involving people. Under the deal, the firms will jointly evaluate the combination in a Phase I clinical trial. They will share development costs.
Decisions on further development will be based on the early-stage study.
The early stages of drug development focus mainly on whether the compound is safe and can reach its intended target.
They normally only involve a small population of patients. Results from later stages of development, involving a higher number of patients, are used to see if a treatment actually works.
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 沪ICP证：沪ICP备05050403号-1
- |
- 互联网新闻信息服务许可证：31120180004
- |
- 网络视听许可证：0909346
- |
- 广播电视节目制作许可证：沪字第354号
- |
- 增值电信业务经营许可证：沪B2-20120012
Copyright © 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
